[Federal Register Volume 67, Number 197 (Thursday, October 10, 2002)]
[Notices]
[Page 63104]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 02-25716]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[30DAY-01-03]


Agency Forms Undergoing Paperwork Reduction Act Review

    The Centers for Disease Control and Prevention (CDC) publishes a 
list of information collection requests under review by the Office of 
Management and Budget (OMB) in compliance with the Paperwork Reduction 
Act (44 U.S.C. Chapter 35). To request a copy of these requests, call 
the CDC Reports Clearance Officer at (404) 498-1210. Send written 
comments to CDC, Desk Officer, Human Resources and Housing Branch, New 
Executive Office Building, Room 10235, Washington, DC 20503. Written 
comments should be received within 30 days of this notice.

Proposed Project

    National Hospital Discharge Survey--(OMB No. 0920-0212)--National 
Center for Health Statistics (NCHS), Centers for Disease Control and 
Prevention (CDC) proposed to conduct a special study to evaluate 
expanding pharmaceutical data in the National Health Care Survey. This 
study is a preliminary investigation of methodological procedures to 
collect information on drugs for inpatients as part of the National 
Hospital Discharge Survey (NHDS). The National Health Care Survey 
currently collects data on drugs prescribed during patient visits to 
physicians' offices and to emergency and outpatient departments through 
the National Ambulatory Medical Care Survey and the National Hospital 
Ambulatory Medical Care Survey. The purpose of this special study is to 
conduct and evaluate a field test of preliminary data collection 
methods using medical records as the source for abstracting names of 
drugs administered to a sample of hospital inpatients. It is 
anticipated that the results of this special study will provide 
essential information regarding: the amount of time and medical 
sophistication required for staff to find and abstract drug data in the 
medical record; the cost of collecting these data as part of the NHDS; 
potential problems to be anticipated in conducting a national survey 
which potentially requires the participation of a large number of 
hospitals; and, what the next steps should be to evaluate the 
possibility of adding drug data to the NHDS. The field test for this 
special study will include a sample of approximately 50 hospitals which 
are not currently participating in the NHDS. Data collection will 
include 20 discharges sampled from one month from each participating 
hospital. The data items to be abstracted are all of the NHDS items in 
addition to listing the narrative description of all drugs administered 
during the sampled inpatient stay. It is anticipated that only half of 
the hospitals which participate in the special study will conduct their 
own abstracting (``Primary procedure'') and that contractor staff will 
perform the abstracting (``Alternate procedure'') in the other 25 
hospitals. The total annual burden for this data collection is 367 
hours.

----------------------------------------------------------------------------------------------------------------
                                                                                                      Average
                                                                    Number of        Number of        burden/
                              Form                                 respondents      responses/     response  (in
                                                                                    respondent        hours)
----------------------------------------------------------------------------------------------------------------
Medical Record Abstract--Primary Procedure Hospital............              25               20           30/60
Medical Record Abstract--Alternate Procedure Hospital..........              25               20            1/60
Induction Form.................................................              50                1               2
Transmittal Form...............................................              50                1           10/60
----------------------------------------------------------------------------------------------------------------


    Dated: October 2, 2002.
Nancy E. Cheal,
Acting Associate Director for Policy, Planning and Evaluation, Centers 
for Disease Control and Prevention.
[FR Doc. 02-25716 Filed 10-9-02; 8:45 am]
BILLING CODE 4163-18-P